ACT500 tablets

DRUG3 trials

Sponsors

Xiamen Amoytop Biotech Co., Ltd.

Conditions

Chronic Hepatitis bMetabolic Dysfunction-associated SteatohepatitisMetabolic Dysfunction-associated Steatotic Liver DiseaseNon-alcoholic Steatohepatitis

Phase 1

Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants

CompletedNCT06716905

Xiamen Amoytop Biotech Co., Ltd.Non-alcoholic Steatohepatitis

Start: 2025-03-06End: 2025-09-22Updated: 2026-02-17

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)

Not yet recruitingNCT07462455

Xiamen Amoytop Biotech Co., Ltd.Metabolic Dysfunction-associated Steatohepatitis

Start: 2026-10-31End: 2027-04-30Target: 24Updated: 2026-09-14

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B

Not yet recruitingNCT07589400

Xiamen Amoytop Biotech Co., Ltd.Chronic Hepatitis b, Metabolic Dysfunction-associated Steatotic Liver Disease

Start: 2026-10-30End: 2027-06-30Target: 24Updated: 2026-09-14